About Mycenax

Mycenax is a CDMO (Contract Development and Manufacturing Organization) company that provides biopharmaceutical services and solutions for drug development and production, with customers in Taiwan, Japan, Korea, Singapore, among other Asia-Pacific regions, as well as Europe and the United States.

With a basis in the production of biosimilars and new biopharmaceuticals, since 2019 Mycenax has shifted to advancing technology platforms as well as building and expanding GMP plants to meet international standards, fulfilling the diverse needs of customers and providing tailor-made and streamlined CDMO services.  

In 2019, Mycenax acquired TPG biologics, integrating their protein gene engineering and cell line technology with Mycenax’s process development and GMP manufacturing experience to establish a complete service for the development and production of biological drugs. Mycenax, as an international CDMO company, continuously invests in innovation for product development technologies and optimization of technology platforms to provide customers with the best CDMO services. 

Each GMP facility is compliance to and implementation as per ICH, EMA, FDA, and PMDA Guidance

Mycenax is a CDMO company that provides

comprehensive and streamlined services for

developability assessment, cell line development,

process development, GMP production, regulatory

documents, etc.